Cascade’s current strategy is focused on bringing novel hypoxia-activated therapies into clinical development with an initial focus on CPD100: a potential first-in- class targeted therapy in wet AMD delivered by a highly localized suprachoroidal injection. This represents a significantly differentiated approach from the existing wet AMD commercial and clinical stage pipeline dominated by anti-VEGF therapeutics delivered by intravitreal injection.
An additional opportunity exists with CPD100Li, a liposomal formulation for IV systemic therapy in patients with tumors prone to hypoxia such as pancreatic and pediatric low- grade glioma.
We are currently exploring investment & partnership opportunities to further development of CPD100 through late preclinical development, IND enabling studies and into the clinic.
For further inquiries, please contact partnering@cascadeprodrug.com.